Journal ID (nlm-ta): Drug Des Devel Ther
Journal ID (iso-abbrev): Drug Des Devel Ther
Journal ID (publisher-id): dddt
Title:
Drug Design, Development and Therapy
Publisher:
Dove
ISSN
(Electronic):
1177-8881
Publication date
(Electronic):
23
October
2021
Publication date Collection: 2021
Volume: 15
Pages: 4423-4434
Affiliations
[1
]The Biotechnology and Drug Development Research Laboratory, Curtin Medical School
& Curtin Health Innovation Research Institute, Curtin University , Bentley, Perth, 6102, WA, Australia
[2
]Hearing Therapeutics, Ear Science Institute Australia, Queen Elizabeth II Medical
Centre , Nedlands, Perth, 6009, WA, Australia
[3
]Fiona Stanley Hospital , Perth, WA, Australia
[4
]Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University , Perth, WA, Australia
[5
]Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine,
University of Novi Sad , Novi Sad, 21101, Serbia
Author notes
Correspondence: Hani Al-Salami Hearing Therapeutics, Biotechnology and Pharmaceutical
Sciences, Curtin University , Bentley, Perth, 6102, WA, Australia
Tel +61 8 9266 9816
Fax + 61 8 9266 2769 Email hani.al-salami@curtin.edu.au
Author information
Article
Publisher ID:
328526
DOI: 10.2147/DDDT.S328526
PMC ID: 8550211
PubMed ID: 34720580
SO-VID: cc33b6f8-1524-41cf-a4ce-cc1f13e3626c
Copyright statement: © 2021 Mooranian et al.
License:
This work is published and licensed by Dove Medical Press Limited. The full terms
of this license are available at
https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0)
License (
http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work
are permitted without any further permission from Dove Medical Press Limited, provided
the work is properly attributed. For permission for commercial use of this work, please
see paragraphs 4.2 and 5 of our Terms (
https://www.dovepress.com/terms.php).
Page count
Figures: 5,
Tables: 1,
References: 70,
Pages: 12
Funded by:
Beijing Nat-Med Biotechnology Co. Ltd;
Funded by:
European Union Horizon 2020 research project;
Funded by:
Curtin Faculty ORS-WAHAI Consortium and the Australian National Health and Medical
Research;
H Al-Salami has been and is currently receiving funding from Beijing Nat-Med Biotechnology
Co. Ltd. The work is partially supported by the European Union Horizon 2020 research
project and innovation program under the Marie Skłodowska-Curie Grant Agreement No
872370. Curtin Faculty ORS-WAHAI Consortium and the Australian National Health and
Medical Research (APP9000597).